Event Overview:
Register for the Gastrointestinal Cancers Symposium and join us for three days of translational research, novel clinical therapies, and state-of-the-art science in GI oncology.
The Gastrointestinal (GI) Cancers Symposium is a specialized oncology event designed to provide scientific and educational content for members of the GI cancer care and research community. This three-day meeting encompasses the latest science in cancers of the esophagus and stomach; the pancreas, small bowel, and hepatobiliary tract; and the colon, rectum, and anus. This year’s Symposium offers new breakout sessions covering cutting-edge and controversial topics, a networking luncheon for early-career oncologists, and the opportunity to view and discuss selected posters with respected faculty members during poster walks.
Exhibitor Information:
The exhibits at the Gastrointestinal Cancers Symposium highlight the most advanced treatments, products, and services in oncology and provide attendees the opportunity to meet with representatives from the healthcare industry, including pharmaceutical companies and advocacy groups.
About ASCO:
Founded in 1964, the American Society of Clinical Oncology is the world's leading professional organization for physicians and oncology professionals caring for people with cancer.
ASCO Promotes and Provides For
Lifelong learning for oncology professionals,
Cancer research,
An improved environment for oncology practice,
Access to quality cancer care,
A global network of oncology expertise, and
Educated and informed patients with cancer.
ASCO is supported by its affiliate organization, the Conquer Cancer Foundation, which funds groundbreaking research and programs that make a tangible difference in the lives of people with cancer.
7:00 AM-8:00 AM |
Complimentary Continental Breakfast |
7:00 AM-6:30 PM |
Exhibits Open |
7:50 AM-9:30 AM |
Welcome and General Session 1: Response Assessment and Individualization of Management of Esophageal Adenocarcinoma (ARS) |
9:30 AM-10:00 AM |
Break |
10:00 AM-11:30 AM |
General Session 2: Global Outlook on Gastric Cancer
Abstract 1: Long-term outcome of a randomized phase III trial exploring the significance of extensive intraoperative peritoneal lavage in addition to standard treatment for ≥ T3 resectable gastric cancer: CCOG 1102. First author: Daishi Morimoto, MD |
11:30 AM-1:00 PM |
Poster Session A: Cancers of the Esophagus and Stomach |
11:30 AM-1:00 PM |
Trials in Progress Poster Session A: Cancers of the Esophagus and Stomach |
12:00 PM-1:00 PM |
Trainee and Early-Career Networking Luncheon |
1:00 PM-2:00 PM |
Rapid-Fire Abstract Session: Cancers of the Esophagus and Stomach Sarah E. Hoffe, MD - Chair Ulysses Ribeiro, Jr., MD, PhD - Chair
Abstract 6: Robot-assisted minimally invasive thoraco-laparoscopic esophagectomy versus open transthoracic esophagectomy for resectable esophageal cancer: A randomized controlled trial. First author: Pieter van der Sluis, MD, PhD, Msc
Question and Answer
Abstract 91: A prospective multicenter trial of S-1 with lafutidine vs S-1 as adjuvant chemotherapy for gastric cancer in Japan: AEOLUS. First author: Nozomu Machida, MD, PhD
Question and Answer
Abstract 8: CYTO-CHIP: Cytoreductive surgery versus cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for gastric cancer with peritoneal metastasis: A propensity-score analysis from BIG RENAPE and FREGAT working groups. First author: Pierre Emmanuel Bonnot, BA
Question and Answer
Abstract 9: Associations of PD-1 and PD-L1 expression with mismatch repair status and prognosis in chemoradiotherapy-naïve esophageal and gastric adenocarcinoma. First author: Maria Svensson, MD, PhD Student
Question and Answer |
1:00 PM-2:00 PM |
Breakout Session: Multidisciplinary Management of Less Common Gastroesophageal Tumors |
1:00 PM-2:00 PM |
Breakout Session: FLOT or Not—Perioperative Management for Gastric Cancer |
2:00 PM-2:15 PM |
Break |
2:15 PM-3:45 PM |
Oral Abstract Session A: Cancers of the Esophagus and Stomach David H. Ilson, MD, PhD - Chair K. Robert Shen, MD - Chair
Abstract 2: The impact of the chemoradiation to surgery interval on pathological complete response: Short and long-term overall survival in esophageal cancer patients. First author: Basem Azab, BA
Abstract 3: Impact of lung and heart dose on survival after radiotherapy for esophageal cancer. First author: Patrick Oh, BSc
Theodore S. Hong, MD NSABP/ NRG Oncology/ Massachusetts General Hospital Discussion
Abstract 4: Intraperitoneal immunotherapy with the bispecific anti-EpCAM x anti-CD3 directed antibody catumaxomab for patients with peritoneal carcinomatosis from gastric cancer: Final results of a randomized phase II AIO trial. First author: Florian Lordick, MD
Late-Breaking Abstract
Stephen Leong, MD University of Colorado Comprehensive Cancer Center Discussion
Panel Question and Answer |
3:45 PM-4:15 PM |
Break |
4:15 PM-5:30 PM |
General Session 3: Is There a Role for Locoregional Therapies in Stage IV Esophageal and Gastric Cancers? (ARS) |
5:30 PM-6:30 PM |
Poster Session A: Cancers of the Esophagus and Stomach |
5:30 PM-6:30 PM |
Trials in Progress Poster Session A: Cancers of the Esophagus and Stomach |
5:45 PM-6:30 PM |
Poster Walks Open to all attendees. Meet at the Poster Assistance Desk.
Khaldoun Almhanna, MD, MPH Moffitt Cancer Center
K. Robert Shen, MD Mayo Clinic |
7:00 AM-8:00 AM |
Complimentary Continental Breakfast |
7:00 AM-6:30 PM |
Exhibits Open |
7:55 AM-9:30 AM |
Welcome and General Session 4: Multimodality Management of Biliary Malignancies |
9:30 AM-10:00 AM |
Break |
10:00 AM-11:30 AM |
General Session 5: Emerging Options for Hepatocellular Carcinoma—A Global Perspective |
11:30 AM-1:00 PM |
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract |
11:30 AM-1:00 PM |
Trials in Progress Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract |
12:00 PM-12:45 PM |
Poster Walks Open to all attendees. Meet at the Poster Assistance Desk.
Ryan Fields, MD, FACS Washington University School of Medicine in St. Louis
Philip Agop Philip, MD, PhD, FRCP Karmanos Caner Institute |
1:00 PM-2:00 PM |
Rapid-Fire Abstract Session: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract Jason C. Cheng, MD, MS, PhD - Chair Shishir Maithel, MD, FACS - Chair
Abstract 208: A phase IB/II randomized study of mFOLFIRINOX (mFFOX) + pegylated recombinant human hyaluronidase (PEGPH20) versus mFFOX alone in patients with good performance status metastatic pancreatic adenocarcinoma (mPC): SWOG S1313 (NCT #01959139). First author: Ramesh Ramanathan, MD
Question and Answer
Abstract 209: KEYNOTE-224: Pembrolizumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib. First author: Andrew Zhu
Question and Answer
Abstract 210: Effect of transarterial chemoembolization plus external beam radiotherapy on survival of patients with hepatocellular carcinoma showing macroscopic vascular invasion compared with sorafenib: A randomized trial. First author: Sang Min Yoon
Question and Answer
Abstract 211: Genomics-driven precision medicine for advanced pancreatic ductal carcinoma (PDAC): Early results from the COMPASS trial (NCT02750657). First author: Kyaw Aung, MBBS, MRCP, PhD
Question and Answer |
1:00 PM-2:00 PM |
Breakout Session: Hereditary Gastrointestinal Cancer Syndromes |
1:00 PM-2:00 PM |
Breakout Session: Minimally Invasive Diagnostic and Interventional Techniques for Pancreaticobiliary Malignancies |
2:00 PM-2:15 PM |
Break |
2:15 PM-3:45 PM |
Oral Abstract Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract Ryan Fields, MD, FACS - Chair Flavio G. Rocha, MD - Chair
Abstract 204: Phase II LAPACT Trial of nab-paclitaxel (nab-P) plus gemcitabine (G) for patients with locally advanced pancreatic cancer (LAPC). First author: Pascal Hammel
Abstract 205: Randomized phase III study of gemcitabine plus S-1 combination therapy versus gemcitabine plus cisplatin combination therapy in advanced biliary tract cancer: A Japan Clinical Oncology Group study (JCOG1113, FUGA-BT). First author: Chigusa Morizane, MD, PhD
Brian M. Wolpin, MD Dana-Farber Cancer Institute Discussion
Abstract 206: Randomized, Open Label, Multicenter, Phase II Trial comparing Transarterial Chemoembolization (TACE) plus Sorafenib with TACE Alone in Patients with Hepatocellular Carcinoma (HCC): TACTICS Trial. First author: Masatoshi Kudo, MD, PhD
Abstract 207: Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: results from the randomized phase 3 CELESTIAL trial. First author: Ghassan Abou-Alfa, MD
Jordi Bruix, MD, PhD University of Barcelona Discussion
Panel Question and Answer |
3:45 PM-4:15 PM |
Break |
4:15 PM-5:30 PM |
General Session 6: Advanced and Metastatic Neuroendocrine Tumors (ARS) |
5:30 PM-6:30 PM |
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract |
5:30 PM-6:30 PM |
Trials in Progress Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract |
7:00 AM-7:55 AM |
Rapid-Fire Abstract Session: Cancers of the Colon, Rectum, and Anus Michael J. Hall, MD, MS - Chair
Abstract 557: Reverce: Randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for metastatic colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin, and irinotecan. First author: Kohei Shitara, MD
Question and Answer
Abstract 558: SCOT: Tumor sidedness and the influence of chemotherapy duration on DFS. First author: Mark Saunders, MD, PhD
Question and Answer
Abstract 559: Effect of physical activity trackers and daily text messages on quality-of-life in colorectal survivors (Smart Pace): A pilot randomized controlled trial. First author: Hilary Chan, BA
Question and Answer
Abstract 560: A phase Ib study of safety and clinical activity of atezolizumab (A) and cobimetinib (C) in patients (pts) with metastatic colorectal cancer (mCRC). First author: Johanna Bendell, MD
Question and Answer |
7:00 AM-7:55 AM |
|
7:00 AM-7:55 AM |
Trials in Progress Poster Session C: Cancers of the Colon, Rectum, and Anus |
7:00 AM-7:55 AM |
Breakout Session: Intraperitoneal Chemotherapy for Intra-abdominal Malignancies |
7:00 AM-7:55 AM |
Breakout Session: Liquid Biopsies—Role in Management of Gastrointestinal Cancers |
7:00 AM-7:55 AM |
Complimentary Continental Breakfast |
7:55 AM-9:30 AM |
Welcome and General Session 7: Early-Onset Colorectal Cancer
Abstract 552: Age distribution of tumor gene expression in patients with stage II/III colon cancer. First author: Howard Hochster, MD
|
9:30 AM-10:00 AM |
Break |
10:00 AM-11:00 AM |
Keynote Lecture: Mapping the Immune Landscape in Pancreatic Cancer |
11:00 AM-12:30 PM |
Oral Abstract Session C: Cancers of the Colon, Rectum, and Anus S. Gail Eckhardt, MD, FASCO - Chair Mary Uan-Sian Feng, MD - Chair
Abstract 553: Nivolumab + ipilimumab combination in patients with DNA mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC): First report of the full cohort from CheckMate-142. First author: Thierry Andre, MD
Abstract 554: Nivolumab in patients with DNA mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC): Long-term survival according to prior line of treatment from CheckMate-142. First author: Michael Overman, MD
Zsofia Kinga Stadler, MD Discussion
Abstract 555: Genetic profile of polyps and risk of advanced metachronous lesions. First author: Oscar Murcia Sr., MD
Abstract 556: Prospective clinical study of circulating tumor cells for colorectal cancer screening. First author: Wen-Sy Tsai, MD, PhD
Douglas Corley, MD, PhD, MPH Discussion
Panel Question and Answer |
12:30 PM-2:00 PM |
Poster Session C: Cancers of the Colon, Rectum, and Anus |
12:30 PM-2:00 PM |
Trials in Progress Poster Session C: Cancers of the Colon, Rectum, and Anus |
1:00 PM-1:45 PM |
Poster Walks Open to all attendees. Meet at the Poster Assistance Desk.
Andrea Cercek, MD
TBD |
2:00 PM-3:00 PM |
General Session 8: Controversies in Adjuvant Therapy for Colorectal Cancer (ARS) |
3:00 PM-3:15 PM |
Break |
3:15 PM-4:30 PM |
General Session 9: Contemporary Management of Colorectal Cancer Liver Metastases (ARS) |
MD
Author